Subscribe

News
Media
Conferences
Publications
Events
CE
Resources
Subscribe

Spotlight -

Community/Retail|

Pharmacy Technician|

William Motley, MD

Articles by William Motley, MD

AAN 2026: Long Half-Life and Long-Acting Injectable, What Pharmacists Should Know About RAP-219's Dosing Advantages for Focal Epilepsy

ByWilliam Motley, MD,Kennedy Ferruggia, Associate Editor

April 24th 2026

Rapport Therapeutics' RAP-219 achieved seizure freedom in 24% of patients with drug-resistant focal epilepsy over 8 weeks in a phase 2 trial.

Latest Updated Articles

AAN 2026: Long Half-Life and Long-Acting Injectable, What Pharmacists Should Know About RAP-219's Dosing Advantages for Focal Epilepsy
April 24th 2026

Trending on Pharmacy Times

ADA 2026: Why Some T2D Patients Don't Respond to GLP-1 RAs—And What Pharmacists Should Screen For

ADA 2026: Semaglutide Add-On Reduces Glycemic Burden, Cardiometabolic Risk in Older Adults With T2D

ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says

New Research Suggests Bempedoic Acid Outperforms Ezetimibe for Heart Health in Patients with Type 2 Diabetes

ADA 2026: Pharmacist CE Programs May Reduce Clinical Inertia in Type 2 Diabetes